Bristol Myers Squibb (NYSE:BMY) announced topline results from the Phase 3 ALOFT-IPF trial, where admilparant demonstrated a statistically significant improvement in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placebo at the 60 mg dose.
Sagimet Biosciences (NASDAQ:SGMT) reported 52-week denifanstat acne results from license partner Ascletis’ Phase 3 extension study, including 57% Investigator’s Global Assessment success.
Profound Medical (NASDAQ:PROF) entered a co-education agreement with Telix Pharmaceuticals to support physician education on imaging-informed prostate care.
Arcutis Biotherapeutics (NASDAQ:ARQT) presented new ZORYVE clinical data in infants with atopic dermatitis and patients with psoriasis at EADV and Fall Clinical.
Teva Pharmaceutical Industries (NYSE:TEVA) received U.S. Food and Drug Administration approval for WELTRUZA, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia.
Valion Bio (NASDAQ:VBIO) and Shear Kershman Laboratories completed formulation work on an oral mucosal version of Entolimod for potential use in radiation emergencies.
Glaukos (NYSE:GKOS) reported positive topline Phase 4 results showing iDose TR plus cataract surgery reduced mean diurnal intraocular pressure by 11.1 mmHg from baseline at Month 3.
Seaport Therapeutics (NASDAQ:SPTX) presented Phase 1 GlyphAgo data showing a statistically significant 6.8-fold increase in agomelatine bioavailability compared with unmodified agomelatine.
MINISO Group (NYSE:MNSO) reported preliminary mainland China gross merchandise value growth of 25%–30% year over year for the third quarter of 2026.
Johnson & Johnson (NYSE:JNJ) reported two-year Phase 3 ICONIC-LEAD results showing at least 72% of ICOTYDE-treated patients achieved PASI 90 at Week 112.
Eli Lilly and Company (NYSE:LLY) reported exploratory Phase 3b results from the TOGETHER-PsO study comparing Taltz plus Zepbound with Taltz alone in adults with moderate-to-severe plaque psoriasis and excess weight.
High Tide (NASDAQ:HITI) completed the acquisition of an established cannabis retail store in Chestermere, Alberta, for $670,000 in cash on October 8, 2026.
